StreetInsider.com News Articles

Allogene Therapeutics Announces Participation in September Investor Conference

Mon, 31 Aug 2026 08:30:00 -0400

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in the following upcoming investor conference in September.

Citi Biopharma Back to School Conference
Wednesday, September 9
5:00 a.m. PT/8:00 a.m. ET

Any available webcasts will be posted to the Company’s website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available

Allogene Therapeutics Announces Participation in September Investor Conference

Mon, 31 Aug 2026 08:30:00 -0400

Citi Biopharma Back to School Conference
Wednesday, September 9
5:00 a.m. PT/8:00 a.m. ET

Any available webcasts will be posted to the Company’s website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available

Form 4 Allogene Therapeutics, For: Aug 21 Filed by: Douglas Earl Martin

Tue, 25 Aug 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260825/26975327.html

Form 4 Allogene Therapeutics, For: Aug 21 Filed by: Douglas Earl Martin

Tue, 25 Aug 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260825/26975327.html

Form 144 Allogene Therapeutics, Filed by: Douglas Earl Martin

Fri, 21 Aug 2026 19:27:00 -0400

si-local-file:///var/storage/secattach/20260821/26962738.html

Form 144 Allogene Therapeutics, Filed by: Douglas Earl Martin

Fri, 21 Aug 2026 19:27:00 -0400

si-local-file:///var/storage/secattach/20260821/26962738.html

Form EFFECT Allogene Therapeutics,

Fri, 21 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260821/26958180.html

Form EFFECT Allogene Therapeutics,

Fri, 21 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260821/26958180.html

Allogene (ALLO) Reiterated at Market Outperform by Citizens: 'ALPHA3 Trial is On-Track'

Mon, 17 Aug 2026 04:15:16 -0400

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $6.00 price target on Allogene (NASDAQ: ALLO).

The analyst commented, "We reiterate our Market Outperform rating for Allogene Therapeutics and our $6 price target based on a discounted EPS and revenue multiples analysis. Recently, Allogene reported 2Q26 earnings and provided operational updates, including that site activation is ahead of schedule and the ALPHA3 trial is on-track for an interim EFS readout in mid-2027. With two assets in the clinic with the potential for valuation driving data read-outs over the next 6-12 months, and a strong cash position of $423.6MM, we view

Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Frazier Life Sciences Public Fund, L.P.

Fri, 14 Aug 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260814/26931538.html

Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Frazier Life Sciences Public Fund, L.P.

Fri, 14 Aug 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260814/26931538.html

Allogene Therapeutics, Inc. (ALLO) Tops Q2 EPS by 4c

Wed, 12 Aug 2026 16:40:24 -0400

Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q2 EPS of ($0.13), $0.04 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $4.64 million versus the consensus estimate of $2.22 thousand.

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.

Allogene Therapeutics (ALLO) files $500M mixed shelf

Wed, 12 Aug 2026 16:30:19 -0400

Allogene Therapeutics (NASDAQ: ALLO) filed $500,000,000 mixed shelf of:

Common Stock
Preferred Stock
Debt Securities
Warrants

Allogene Therapeutics (ALLO) files $500M mixed shelf

Wed, 12 Aug 2026 16:30:19 -0400

Allogene Therapeutics (NASDAQ: ALLO) filed $500,000,000 mixed shelf of:

Common Stock
Preferred Stock
Debt Securities
Warrants

Form S-3 Allogene Therapeutics,

Wed, 12 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260812/26913295.html

Form S-3 Allogene Therapeutics,

Wed, 12 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260812/26913295.html

Form 10-Q Allogene Therapeutics, For: Jun 30

Wed, 12 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260812/26913181.html

Form 10-Q Allogene Therapeutics, For: Jun 30

Wed, 12 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260812/26913181.html

Form 8-K Allogene Therapeutics, For: Aug 12

Wed, 12 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260812/26912977.html

Form 8-K Allogene Therapeutics, For: Aug 12

Wed, 12 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260812/26912977.html

Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

Wed, 12 Aug 2026 16:05:00 -0400

Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL):
- Recent Interim Futility Analysis Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided 1L Consolidation Therapy
- Strong Execution and Increased Investigator Interest Accelerated 2026 Site Activation Target by Six Months; Approximately 100 Sites Now Expected by Year-End, Further Supporting Enrollment
- Next Update Anticipated in Mid-2027, with Trial Enrollment Expected to Be Completed by Year-End 2027
- Following Review of the Interim Futility Analysis, FDA Granted RMAT and Fast Track Designations for Cema-Cel Underscoring MRD Positivity as an Unmet Need in LBCL
Phase 1 RESOLUTION Trial in Autoimmune Disease:

Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

Wed, 12 Aug 2026 16:05:00 -0400

Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL):
- Recent Interim Futility Analysis Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided 1L Consolidation Therapy
- Strong Execution and Increased Investigator Interest Accelerated 2026 Site Activation Target by Six Months; Approximately 100 Sites Now Expected by Year-End, Further Supporting Enrollment
- Next Update Anticipated in Mid-2027, with Trial Enrollment Expected to Be Completed by Year-End 2027
- Following Review of the Interim Futility Analysis, FDA Granted RMAT and Fast Track Designations for Cema-Cel Underscoring MRD Positivity as an Unmet Need in LBCL
Phase 1 RESOLUTION Trial in Autoimmune Disease:

Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Belldegrun Arie

Fri, 07 Aug 2026 20:20:00 -0400

si-local-file:///var/storage/secattach/20260807/26892536.html

Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Belldegrun Arie

Fri, 07 Aug 2026 20:20:00 -0400

si-local-file:///var/storage/secattach/20260807/26892536.html

Form SCHEDULE 13G Allogene Therapeutics, Filed by: STATE STREET CORP

Fri, 07 Aug 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260807/26888072.html